Global trends in symptomatic medication use against dementia in 66 countries/regions from 2008 to 2018.
Alzheimer's disease
acetylcholinesterase inhibitor
dementia
epidemiology
global neurology
memantine
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
30
07
2021
received:
16
07
2021
accepted:
01
08
2021
pubmed:
8
8
2021
medline:
2
4
2022
entrez:
7
8
2021
Statut:
ppublish
Résumé
The aim was to determine trends and patterns of symptomatic medication used against dementia in 66 countries and regions. This was a cross-sectional study that used the wholesale data from the IQVIA Multinational Integrated Data Analysis System database. Sale data for symptomatic medication against dementia from 66 countries and regions from 2008 to 2018 were analysed and stratified by income level (low/middle-income countries [LMICs], n = 27; high-income countries [HICs], n = 37; regions, n = 2). The medication use volume was estimated by defined daily dose (DDD) per 1000 inhabitants per day (World Health Organization DDD harmonized the size, strength and form of each pack and reflects average dosing). Changes in medication use over time were quantified as percentage changes in compound annual growth rates (CAGRs). Total symptomatic medication against dementia sales increased from 0.85 to 1.33 DDD per 1000 inhabitants per day between 2008 and 2018 (LMICs 0.094-0.396; HICs 3.88-5.04), which is an increase of CAGR of 4.53% per year. The increase was mainly driven by the LMICs (CAGR = 15.42%) in comparison to the HICs (CAGR = 2.65%). The overall medication use from 2008 to 2018 increased for all four agents: memantine (CAGR = 8.51%), rivastigmine (CAGR = 6.91%), donepezil (CAGR = 2.72%) and galantamine (CAGR = 0.695%). In 2018, the most commonly used medication globally was donepezil, contributing to 49.8% of total use volume, followed by memantine (32.7%), rivastigmine (11.24%) and galantamine (6.36%). There was an increasing trend in the use of symptomatic medications against dementia globally, but the use remained low in LMICs. Interventions may be needed to support the medication use in some countries.
Sections du résumé
BACKGROUND AND PURPOSE
The aim was to determine trends and patterns of symptomatic medication used against dementia in 66 countries and regions.
METHODS
This was a cross-sectional study that used the wholesale data from the IQVIA Multinational Integrated Data Analysis System database. Sale data for symptomatic medication against dementia from 66 countries and regions from 2008 to 2018 were analysed and stratified by income level (low/middle-income countries [LMICs], n = 27; high-income countries [HICs], n = 37; regions, n = 2). The medication use volume was estimated by defined daily dose (DDD) per 1000 inhabitants per day (World Health Organization DDD harmonized the size, strength and form of each pack and reflects average dosing). Changes in medication use over time were quantified as percentage changes in compound annual growth rates (CAGRs).
RESULTS
Total symptomatic medication against dementia sales increased from 0.85 to 1.33 DDD per 1000 inhabitants per day between 2008 and 2018 (LMICs 0.094-0.396; HICs 3.88-5.04), which is an increase of CAGR of 4.53% per year. The increase was mainly driven by the LMICs (CAGR = 15.42%) in comparison to the HICs (CAGR = 2.65%). The overall medication use from 2008 to 2018 increased for all four agents: memantine (CAGR = 8.51%), rivastigmine (CAGR = 6.91%), donepezil (CAGR = 2.72%) and galantamine (CAGR = 0.695%). In 2018, the most commonly used medication globally was donepezil, contributing to 49.8% of total use volume, followed by memantine (32.7%), rivastigmine (11.24%) and galantamine (6.36%).
CONCLUSION
There was an increasing trend in the use of symptomatic medications against dementia globally, but the use remained low in LMICs. Interventions may be needed to support the medication use in some countries.
Substances chimiques
Cholinesterase Inhibitors
0
Indans
0
Phenylcarbamates
0
Piperidines
0
Memantine
W8O17SJF3T
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3979-3989Subventions
Organisme : Medical Research Council
ID : G106/1249
Pays : United Kingdom
Informations de copyright
© 2021 European Academy of Neurology.
Références
Donegan K, Fox N, Black N, Livingston G, Banerjee S, Burns A. Trends in diagnosis and treatment for people with dementia in the UK from 2005 to 2015: a longitudinal retrospective cohort study. Lancet Public Health. 2017;2(3):e149-e156.
World Health Organization. Global Action Plan on the Public Health Response to Dementia 2017-2025. World Health Organization; 2017.
World Population Ageing 2017 - Highlights. United Nations, Department of Economic and Social Affairs, Population Division, Department of Economic and Social Affairs PD; 2017. Report No.: ST/ESA/SER.A/397 Contract No.: ST/ESA/SER.A/397.
Martin Prince AW, Guerchet M, Ali G-C, Yu-Tzu WU, Prina M. World Alzheimer Report 2015, The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer’s Disease International; 2015.
Prince M, Acosta D, Albanese E, et al. Ageing and dementia in low and middle income countries-using research to engage with public and policy makers. Int Rev Psychiatry. 2008;20(4):332-343.
Martin Prince MP, Guerchet M. World Alzheimer Report 2013-Journey of Caring: An Analysis of Long-Term Care for Dementia. Alzheimer’s Disease International; 2013.
Perera G, Khondoker M, Broadbent M, Breen G, Stewart R. Factors associated with response to acetylcholinesterase inhibition in dementia: a cohort study from a secondary mental health care case register in London. PLoS One. 2014;9(11):e109484.
Xu H, Garcia-Ptacek S, Jönsson L, Wimo A, Nordstrom P, Eriksdotter M. Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology. 2021;96(17):e2220-e2230.
Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366(10):893-903.
Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2018;6:CD001190.
McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019;3:CD003154.
Knight R, Khondoker M, Magill N, Stewart R, Landau S. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dement Geriatr Cogn Disord. 2018;45(3-4):131-151.
Tan ECK, Johnell K, Garcia-Ptacek S, et al. Acetylcholinesterase inhibitors and risk of stroke and death in people with dementia. Alzheimers Dement. 2018;14(7):944-951.
Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease. Eur Heart J. 2013;34(33):2585-2591.
Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17(10):1236-1248.
Qaseem A, Snow V, Cross JT Jr, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370-378.
National Institute for Health and Care Excellence [NICE]. Dementia: Assessment, Management and Support for People Living with Dementia and Their Carers. NICE guideline: 2018.
Wucherer D, Eichler T, Kilimann I, et al. Antidementia drug treatment in people screened positive for dementia in primary care. J Alzheimers Dis. 2015;44(3):1015-1021.
Koller D, Hua T, Bynum JP. Treatment patterns with antidementia drugs in the United States: Medicare cohort study. J Am Geriatr Soc. 2016;64(8):1540-1548.
Calvo-Perxas L, Turro-Garriga O, Vilalta-Franch J, et al. Trends in the prescription and long-term utilization of antidementia drugs among patients with Alzheimer's disease in Spain: a cohort study using the Registry of Dementias of Girona. Drugs Aging. 2017;34(4):303-310.
Yu L, Chen X, Yu Z. Trends of antidementia drugs use in outpatients with Alzheimer's disease in six major cities of China: 2012-2017. Int Clin Psychopharmacol. 2019;34(6):312-316.
Kostev K, Osina G. Treatment patterns of patients with all-cause dementia in Russia. J Alzheimers Dis Rep. 2020;4(1):9-14.
Cook MN. Estimating national drug consumption using data at different points in the pharmaceutical supply chain. Pharmacoepidemiol Drug Saf. 2006;15(10):754-757.
IQVIA. ACTS: IQVIA Quality assurance 2019 [Available from https://www.iqvia.com/landing/acts]
Hsia Y, Sharland M, Jackson C, Wong ICK, Magrini N, Bielicki JA. Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infect Dis. 2019;19(1):67-75.
Yan VKC, Blais JE, Li X, et al. Trends in cardiovascular medicine use in 65 middle- and high-income countries. J Am Coll Cardiol. 2021;77(7):1021-1023.
World Bank Open Data [Available from: https://data.worldbank.org/]
Collaborators GBDD. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88-106.
National Institute for Health and Care Excellence [NICE]. Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease. NICE guideline; 2011.
Prince M, Ferri CP, Acosta D, et al. The protocols for the 10/66 Dementia Research Group population-based research programme. BMC Public Health. 2007;7:165.
Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008;7(9):812-826.
Cooper C, Lodwick R, Walters K, et al. Observational cohort study: deprivation and access to anti-dementia drugs in the UK. Age Ageing. 2016;45(1):148-154.
Lind KE, Hildreth K, Lindrooth R, Morrato E, Crane LA, Perraillon MC. Effect of Medicare part D on ethnoracial disparities in antidementia medication use. J Am Geriatr Soc. 2018;66(9):1760-1767.
Suh GH, Wimo A, Gauthier S, et al. International price comparisons of Alzheimer's drugs: a way to close the affordability gap. Int Psychogeriatr. 2009;21(6):1116-1126.
Bent-Ennakhil N, Coste F, Xie L, et al. A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer's disease patients. Neurol Ther. 2017;6(1):131-144.
Atri A, Hendrix SB, Pejovic V, et al. Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: a pooled area under the curve analysis. Alzheimers Res Ther. 2015;7(1):28.
Deardorff WJ, Grossberg GT. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease. Drug Des Devel Ther. 2016;10:3267-3279.
Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322(16):1589-1599.
Hernandez I, Zhang Y. Pharmaceutical use and spending trend in Medicare beneficiaries with dementia, from 2006 to 2012. Gerontol Geriatr Med. 2017;3:2333721417704946.
Maxwell CJ, Stock K, Seitz D, Herrmann N. Persistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factors. Can J Psychiatry. 2014;59(12):624-631.
Walsh S, King E, Brayne C. France removes state funding for dementia drugs. BMJ. 2019;367:l6930.
Médicaments de la maladie d'Alzheimer: enfin non remboursables en France! Prescrire. 2018;(38):416.
The Lancet. The collapse of the Venezuelan health system. Lancet. 2018;391(10128):1331.
Langa KM, Larson EB, Crimmins EM, et al. A comparison of the prevalence of dementia in the United States in 2000 and 2012. JAMA Intern Med. 2017;177(1):51-58.
Chang F, Patel T, Schulz ME. The ‘Rising Tide’ of dementia in Canada: what does it mean for pharmacists and the people they care for? Can Pharm J (Ott). 2015;148(4):193-199.
Walker VM, Davies NM, Kehoe PG, Martin RM. What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink. Alzheimers Res Ther. 2018;10(1):51.
Alzheimer Europe. National Care Pathways for People with Dementia Living at Home. Alzheimer Europe; 2014.
Georges J. The availability of antidementia drugs in Europe. Eur Neurol Rev. 2007;(1):40.
The pharmacological management of Alzheimer’s disease-BPJ Issue 30 Bpac.org.nz [Available from: https://bpac.org.nz/BPJ/2010/August/alzheimers.aspx]
Martinez C, Jones RW, Rietbrock S. Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open. 2013;3(1):e002080.